Outcome of Keros Therapeutics TROPOS trial by Q2 2025?
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial halted • 25%
Keros Therapeutics official press releases or regulatory filings
Keros Therapeutics Halts Dosing in Phase 2 PAH Trial Due to Safety Concerns
Dec 12, 2024, 12:02 PM
Keros Therapeutics Inc. (Nasdaq: KROS) has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its ongoing Phase 2 TROPOS trial due to safety concerns related to pericardial effusion adverse events. The trial, which evaluates cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH), remains fully enrolled. Dosing in the 1.5 mg/kg treatment arm continues following a risk and benefit assessment by the independent Data Monitoring Committee (DMC). The company has informed investigators and regulatory authorities, including the FDA, of this decision and plans to present topline data from all treatment arms in the second quarter of 2025. Shares of Keros Therapeutics plunged following the announcement.
View original story
Successful • 25%
Unsuccessful • 25%
Not Announced • 25%
Partially Successful • 25%
Negative efficacy and safety concerns • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
No • 50%
Yes • 50%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Negative results • 25%
Positive results • 25%
Trial extended • 25%
Inconclusive results • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Significant improvement • 25%
Success in primary endpoint only • 25%
Failure in both endpoints • 25%
Success in secondary endpoint only • 25%
Success in both primary and secondary endpoints • 25%
Positive results leading to Phase 2 • 25%
Other outcome • 25%
Negative results halting development • 25%
Neutral results requiring further study • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Positive results with MRD-negative CR • 25%
Approve continuation • 25%
No action taken • 25%
Suspend trial • 25%
Request modifications • 25%